Arménie - anglais - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

accord healthcare limited - captopril - tablets - 12,5mg

Arménie - anglais - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

accord healthcare limited - captopril - tablets - 12,5mg

Canada - anglais - Health Canada

pharmascience inc - captopril - tablet - 12.5mg - captopril 12.5mg - angiotensin-converting enzyme inhibitors

États-Unis - anglais - NLM (National Library of Medicine)

wockhardt limited - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd) - captopril 12.5 mg - hypertension: captopril tablets, usp are indicated for the treatment of hypertension. in using captopril, consideration should be given to the risk of neutropenia/agranulocytosis (see warnings ). captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. in patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. heart failure: captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. the beneficial effect of captopril in heart failure does not require the presence

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - captopril 5 mg/ml - oral solution - 5 mg/ml - active: captopril 5 mg/ml excipient: citric acid monohydrate disodium edetate purified water sodium benzoate sodium citrate - dp-captopril is indicated for the treatment of hypertension. in using dp-captopril, consideration should be given to the risk of neutropenia/agranulocytosis (see section 4.4 special warnings and precautions for use). dp-captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive.

États-Unis - anglais - NLM (National Library of Medicine)

golden state medical supply, inc. - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd) - captopril 12.5 mg

Canada - anglais - Health Canada

pro doc limitee - captopril - tablet - 12.5mg - captopril 12.5mg - angiotensin-converting enzyme inhibitors

Australie - anglais - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - captopril, quantity: 12.5 mg - tablet, uncoated - excipient ingredients: lactose; microcrystalline cellulose; maize starch; palmitic acid; colloidal anhydrous silica; purified talc - hypertension: captopril (captopril) is indicated for the treatment of hypertension. in using captopril, consideration should be given to the risk of neutropenia/agranulocytosis (see warnings). captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. myocardial infarction: captopril (captopril) is indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, manifested as an ejection fraction less than or equal to 40%, and to reduce the incidence of overt heart failure and subsequent hospitalisations for congestive heart failure in these patients. the efficacy data for the use of captopril following myocardial infarction are strongest for initiation of therapy beyond three days post-infarction. heart failure: captopril (captopril) is indicated for the treatment of heart failure. in symptomatic patients it is recommended that captopril be administered together with a diuretic. diabetic nephropathy: captopril (captopril) is indicated for the treatment of diabetic nephropathy in patients with type i insulin-dependent diabetes mellitus.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - captopril, quantity: 12.5 mg - tablet, uncoated - excipient ingredients: lactose; microcrystalline cellulose; maize starch; palmitic acid; colloidal anhydrous silica; purified talc - hypertension: captopril (captopril) is indicated for the treatment of hypertension. in using captopril, consideration should be given to the risk of neutropenia/agranulocytosis (see warnings). captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. myocardial infarction: captopril (captopril) is indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, manifested as an ejection fraction less than or equal to 40%, and to reduce the incidence of overt heart failure and subsequent hospitalisations for congestive heart failure in these patients. the efficacy data for the use of captopril following myocardial infarction are strongest for initiation of therapy beyond three days post-infarction. heart failure: captopril (captopril) is indicated for the treatment of heart failure. in symptomatic patients it is recommended that captopril be administered together with a diuretic. diabetic nephropathy: captopril (captopril) is indicated for the treatment of diabetic nephropathy in patients with type i insulin-dependent diabetes mellitus.

Canada - anglais - Health Canada

laboratoires trianon inc. - captopril - tablet - 12.5mg - captopril 12.5mg - angiotensin-converting enzyme inhibitors